Efficacy and Toxicity of Factor Xa Inhibitors

Efficacy and Toxicity of Factor Xa Inhibitors

Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority. New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed...

Full description

Bibliographic Details
Main Authors:	Maryna Bondarenko, Christophe Curti, Marc Montana, Pascal Rathelot, Patrice Vanelle
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-02-01
Series:	Journal of Pharmacy & Pharmaceutical Sciences
Online Access:	https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/18644

Similar Items

Organic Glues or Fibrin Glues from Pooled Plasma: Efficacy, Safety and Potential as Scaffold Delivery Systems
by: Clémence Tabélé, et al.
Published: (2012-01-01)

Development and evaluation of an elective course on the pharmacist’s role in disaster management in France
by: Marc Montana, et al.
Published: (2019-07-01)

Synthesis of 3-Alkenyl-1-azaanthraquinones via Diels-Alder and Electron Transfer Reactions
by: Patrice Vanelle, et al.
Published: (2002-12-01)

31st Annual GP<sub>2</sub>A Medicinal Chemistry Conference
by: Nicolas Primas, et al.
Published: (2024-02-01)

New Methodology for the Synthesis of Thiobarbiturates Mediated by Manganese(III) Acetate
by: Patrice Vanelle, et al.
Published: (2012-04-01)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
by: Daniël Verhoef, et al.
Published: (2017-09-01)

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors
by: Milan Remko, et al.
Published: (2016-02-01)

Direct factor Xa inhibitor in the prevention of thromboembolism
by: Viktor Meretskyi, et al.
Published: (2019-01-01)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
by: Persson PB
Published: (2015-05-01)

Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation
by: Mahtani, K, et al.
Published: (2017)

Discovery and development of Factor Xa inhibitors (2015–2022)
by: Wei Zheng, et al.
Published: (2023-02-01)

The role of factor Xa inhibitors in venous thromboembolism treatment
by: Cabral KP, et al.
Published: (2015-01-01)

<i>N</i>-[1-(2-Chlorophenyl)-2-{1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1<i>H</i>-imidazol-2-yl}ethyl]-4-methylbenzenesulfonamide
by: Romain Paoli-Lombardo, et al.
Published: (2023-04-01)

Access to Original Vinylic Chlorides in the Quinazoline Series via a Monoelectronic Transfer Reaction Approach
by: Martine Maillard-Boyer, et al.
Published: (2010-04-01)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
by: Elise Carpenter, et al.
Published: (2019-11-01)

Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys
by: Pancras C. Wong, et al.
Published: (2021-05-01)

Quinoxaline Derivatives as Antiviral Agents: A Systematic Review
by: Marc Montana, et al.
Published: (2020-06-01)

Quinoxaline Moiety: A Potential Scaffold against <i>Mycobacterium tuberculosis</i>
by: Marc Montana, et al.
Published: (2021-08-01)

The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases
by: Shohei Hamada, et al.
Published: (2024-02-01)

Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells
by: Ryoichi Sohma, et al.
Published: (2023-06-01)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
by: Upreti VV, et al.
Published: (2013-04-01)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
by: Kaatz S, et al.
Published: (2017-09-01)

A Survey of Synthetic Routes and Antitumor Activities for Benzo[<i>g</i>]quinoxaline-5,10-diones
by: Alain G. Giuglio-Tonolo, et al.
Published: (2020-12-01)

Cross-Coupling Synthesis of Methylallyl Alkenes: Scope Extension and Mechanistic Study
by: Clémence Tabélé, et al.
Published: (2015-12-01)

Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range
by: N V Seredavkina, et al.
Published: (2019-05-01)

Plasmodial Kinase Inhibitors Targeting Malaria: Recent Developments
by: Romain Mustière, et al.
Published: (2020-12-01)

Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa
by: Go Oun Kim, et al.
Published: (2023-04-01)

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
by: Sebastian Rauch, et al.
Published: (2022-06-01)

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study
by: Eva N. Hamulyák, et al.
Published: (2021-01-01)

A Study on the Effects of Dırect Factor Xa Inhibitors and Direct Thrombin Inhibitors on Human Primary Chondrocyte Cultures
by: Yasin Emre KAYA, et al.
Published: (2019-12-01)

Assessing the Role of a Malonamide Linker in the Design of Potent Dual Inhibitors of Factor Xa and Cholinesterases
by: Rosa Purgatorio, et al.
Published: (2022-07-01)

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland
by: Anne Angelillo-Scherrer, et al.
Published: (2023-07-01)

Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study
by: Nina Haagenrud Schultz MD, PhD, et al.
Published: (2021-05-01)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
by: Katarzyna Papaj, et al.
Published: (2022-01-01)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease.
by: Katarzyna Papaj, et al.
Published: (2022-01-01)

Efficacy and tolerance of selective and non-selective factor Xa inhibitors in the prevention of thrombosis in kidney disease in patients with systemic lupus erythematosus and antiphospholipid syndrome
by: N. V. Seredavkina, et al.
Published: (2019-03-01)

Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro
by: Herm Jan M. Brinkman, et al.
Published: (2022-03-01)

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
by: Jing Tao, et al.
Published: (2018-06-01)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
by: Victoria M. Stevens PharmD, BCCCP, et al.
Published: (2021-09-01)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
by: Megan A. Rech, et al.
Published: (2020-12-01)